When: Close below $122 (50 SMA break)

Then: Downgrade to Underweight — thesis invalidation

When: Q3/Q4 earnings fail to validate $9.56 forward EPS path

Then: Downgrade to Sell — structural floor breaks

When: 200 SMA test at ~$113 with positive MACD divergence

Then: High-conviction reload — structural re-entry at deep discount

HOLD existing positions; ADD new capital only at $118-$122 (5-10% pullback from current levels)

• Stock at $135, up 70% from December lows, testing upper Bollinger Band at $136.53 with RSI at 65.94 approaching overbought
• New high printed on volume of 8.12 million shares, well below the 13-19 million shares that fueled prior breakout runs
• Forward PE of 14 based on $9.56 EPS estimate; if Merck misses by 10% (EPS of $8.60), forward PE becomes 16
• FCF declined 32% year-over-year to $12.4 billion versus $18.1 billion prior year; operating cash flow down from $21.47B to $16.47B
• Merck returned $13.3 billion to shareholders in 2025 against FCF of $12.3 billion—returned more than generated, funded gap with leverage
• Net debt up 46% year-over-year to $34.77 billion; debt-to-equity ratio at 0.94
• 30-year Treasury yield at 19-year high; prediction markets pricing 85% probability of zero Fed cuts in 2026
• Q2 net loss of $1.335 billion tied to IPR&D and acquisition activity as company accelerates spending ahead of patent cliff
• Patent cliff for Keytruda (2028) asymmetry: can lose 15-20% if narrative reasserts, gain only 10-15% if bull case plays out
• Conservative entry zone of $118-$122 represents 13x forward PE versus current 14x; ATR is 3.24 making the $130 stop (1.2 ATR) inadequate risk management
• 50 SMA at $126 is still $9.2 above conservative target, and adding at $133-$137 is not a pullback entry

→ vs aggressive: Forward PE of 14 is a forecast, not a fact—if EPS misses by 10%, the multiple expands to 16x; current technicals show weakest volume signature of the rally at upper Bollinger Band

→ vs aggressive: FCF decline of 32% is not a 'gym set'—the company returned $13.3B against $12.3B FCF, funding the gap with leverage, a pattern that breaks when cash flows contract and rates stay elevated

→ vs aggressive: Net debt up 46% into sustained high-rate environment is reduced margin of safety, not strategic capital deployment; should de-lever before patent cliff, not lever into it

→ vs aggressive: Patent cliff is not 'already digested'—market starts pricing LOE 3-4 years ahead; company accelerating spend to deal with cliff signals urgency, not confidence

→ vs aggressive: Entry plan requires pullback to 50 SMA at $126 to add, which contradicts conviction entry at current levels and still sits above conservative target by $9.2

→ vs neutral: Add on pullbacks to $133-$137 is not conservative—adding at roughly current price provides no additional safety; real pullback entry is 5-10% below current levels at $118-$122

HOLD existing positions; stage new entries at 131-133, 126-128, and above 140

• 14x forward PE is reasonable for defensive pharma but 108x TTM PE signals modest premium over fair value
• 32 percent FCF decline is temporary strategic pressure, not structural deterioration; underlying operating cash flow of 16.47 billion remains robust
• New high at 137.98 on only 8.12 million shares versus 13 to 19 million for prior breakouts is the single most important near-term warning
• Patent cliff for Keytruda meaningfully impacts revenue in 2028 but market begins pricing 12 to 24 months prior, putting current period in that window
• 10 EMA at 133.08 and VWMA at 131.05 are validated pullback zones; 50 SMA at 126 is medium-term trend support; 200 SMA at 113 is major structural support below
• Breakout above 140 on volume greater than 12 million shares opens path to 145 and potentially upper analyst price target band at 155
• ATR of 3.24 means tight stop at 130 is only 1.2 ATR—a noise filter, not a real stop; 122 provides approximately 4 ATR of room
• Conservative analyst's 118-122 target has no technical basis; it's a fundamental valuation target dressed as a technical entry
• Sustained 5 percent plus 30-year yield environment with 85 percent probability of zero Fed cuts creates multiple compression risk for defensives
• Position sizing: 30-40 percent starter at 131-133, 30-40 percent add at 126-128, 20-30 percent reserved for 140 breakout

→ vs aggressive: Calling patent cliff 'already digested' is wrong; Keytruda exclusivity loss begins impacting revenue in 2028 but market starts pricing it 12 to 24 months prior

→ vs aggressive: Stop at 130 is only 3.7 percent below current and 1.2 ATR, which will get clipped on any normal 3 to 4 dollar pullback day

→ vs aggressive: Aggressive add at 126 is consistent with conservative entry—the psychological framing differs but actual levels overlap

→ vs conservative: Waiting for 118 to 122 while simultaneously holding existing positions because uptrend is intact is incoherent; those levels would only be reached if the uptrend broke

→ vs conservative: 'Wait for 118 to 122' target has no technical basis; that's a fundamental valuation target dressed up as a technical entry

→ vs conservative: Calling 32 percent FCF decline 'structural deterioration' is overreach; working capital build and M&A integration are temporary factors